Jay S. Skyler

26.7k total citations · 11 hit papers
272 papers, 16.9k citations indexed

About

Jay S. Skyler is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Surgery. According to data from OpenAlex, Jay S. Skyler has authored 272 papers receiving a total of 16.9k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Endocrinology, Diabetes and Metabolism, 128 papers in Genetics and 118 papers in Surgery. Recurrent topics in Jay S. Skyler's work include Diabetes Management and Research (170 papers), Diabetes and associated disorders (126 papers) and Pancreatic function and diabetes (113 papers). Jay S. Skyler is often cited by papers focused on Diabetes Management and Research (170 papers), Diabetes and associated disorders (126 papers) and Pancreatic function and diabetes (113 papers). Jay S. Skyler collaborates with scholars based in United States, Canada and United Kingdom. Jay S. Skyler's co-authors include Jay M. Sosenko, Carla J. Greenbaum, Desmond Schatz, Jeffrey P. Krischer, Jerry P. Palmer, Peter A. Gottlieb, Kevan C. Herold, Jennifer B. Marks, John M. Lachin and M. Sue Kirkman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Jay S. Skyler

264 papers receiving 16.2k citations

Hit Papers

Rituximab, B-Lymphocyte D... 2002 2026 2010 2018 2009 2015 2008 2020 2002 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
    2009 781 citations Mark D. Pescovitz, Carla J. Greenbaum et al. profile →
  2. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
    2015 735 citations Mark A. Atkinson, Peter A. Gottlieb et al. Diabetes Care profile →
  3. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
    2008 637 citations Jay S. Skyler, Richard M. Bergenstal et al. Diabetes Care profile →
  4. Practical recommendations for the management of diabetes in patients with COVID-19
    2020 611 citations Richard I. G. Holt, Jay S. Skyler et al. profile →
  5. Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus
    2002 590 citations Jay S. Skyler profile →
  6. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
    2016 505 citations Jay S. Skyler, Per‐Henrik Groop et al. Diabetes profile →
  7. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
    2011 428 citations Stephen E. Gitelman, Peter A. Gottlieb et al. profile →
  8. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2021 349 citations Richard I. G. Holt, J. Hans DeVries et al. Diabetes Care profile →
  9. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
    2017 275 citations Jay S. Skyler, John B. Buse et al. Diabetes Care profile →
  10. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
    2018 244 citations David Z.I. Cherney, Jay S. Skyler et al. Diabetes Care profile →
  11. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2021 225 citations Richard I. G. Holt, J. Hans DeVries et al. Diabetologia profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jay S. Skyler 11.2k 7.9k 7.7k 1.8k 1.3k 272 16.9k
Paolo Pozzilli 6.9k 0.6× 6.4k 0.8× 5.6k 0.7× 2.4k 1.3× 1.7k 1.3× 443 14.3k
Marian Rewers 10.6k 0.9× 11.1k 1.4× 8.8k 1.1× 2.0k 1.1× 1.6k 1.2× 367 20.5k
Desmond Schatz 9.4k 0.8× 11.0k 1.4× 8.6k 1.1× 3.4k 1.9× 1.4k 1.0× 301 17.8k
David M. Maahs 12.7k 1.1× 7.3k 0.9× 7.2k 0.9× 971 0.5× 1.2k 0.9× 369 17.5k
David M. Nathan 12.3k 1.1× 4.2k 0.5× 4.3k 0.6× 2.3k 1.3× 1.8k 1.3× 124 17.1k
James H. Warram 6.4k 0.6× 3.8k 0.5× 3.5k 0.5× 3.5k 2.0× 2.5k 1.8× 190 17.3k
H. Peter Chase 5.9k 0.5× 4.4k 0.6× 4.2k 0.6× 735 0.4× 724 0.5× 204 9.6k
Santica M. Marcovina 11.5k 1.0× 4.3k 0.5× 12.4k 1.6× 3.3k 1.9× 2.4k 1.8× 406 25.5k
Abbas E. Kitabchi 9.0k 0.8× 4.8k 0.6× 3.0k 0.4× 2.9k 1.7× 3.2k 2.4× 237 15.6k
Zhiguang Zhou 5.7k 0.5× 3.8k 0.5× 3.8k 0.5× 4.8k 2.7× 1.6k 1.2× 465 15.2k

Countries citing papers authored by Jay S. Skyler

Since Specialization
Citations

This map shows the geographic impact of Jay S. Skyler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay S. Skyler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay S. Skyler more than expected).

Fields of papers citing papers by Jay S. Skyler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay S. Skyler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay S. Skyler. The network helps show where Jay S. Skyler may publish in the future.

Co-authorship network of co-authors of Jay S. Skyler

This figure shows the co-authorship network connecting the top 25 collaborators of Jay S. Skyler. A scholar is included among the top collaborators of Jay S. Skyler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay S. Skyler. Jay S. Skyler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bergenstal, Richard M., Adam Heller, Marc D. Breton, et al.. (2025). Evolution of the Artificial Pancreas: Components and Integration—CGMs, Insulin, and AP Systems. Journal of Diabetes Science and Technology. 19(4). 883–894. 1 indexed citations
2.
Sosenko, Jay M., David Cuthbertson, Laura M. Jacobsen, et al.. (2025). A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts. Diabetes Technology & Therapeutics. 27(3). 179–186.
3.
Zhao, Lue Ping, George K. Papadopoulos, Jay S. Skyler, et al.. (2024). Progression to type 1 diabetes in the DPT-1 and TN07 clinical trials is critically associated with specific residues in HLA-DQA1-B1 heterodimers. Diabetologia. 67(11). 2481–2493.
4.
Gaglia, Jason L., Heather Daley, Jerome Ritz, et al.. (2024). Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes. NEJM Evidence. 3(7). EVIDoa2300238–EVIDoa2300238. 5 indexed citations
5.
Latres, Esther, Carla J. Greenbaum, Colin Dayan, et al.. (2024). Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes. 73(6). 823–833. 15 indexed citations
6.
Sridhar, Vikas S., Christine P. Limonte, Per‐Henrik Groop, et al.. (2023). Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes. Diabetologia. 67(1). 3–18. 17 indexed citations
7.
Sosenko, Jay M., David Cuthbertson, Emily K. Sims, et al.. (2023). Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies. Diabetes Care. 46(5). 1098–1105. 9 indexed citations
8.
Sims, Emily K., David Cuthbertson, Jamie L. Felton, et al.. (2022). Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening. Diabetes Care. 45(12). 2982–2990. 5 indexed citations
9.
10.
Holt, Richard I. G., J. Hans DeVries, Amy Hess-Fischl, et al.. (2021). The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 64(12). 2609–2652. 225 indexed citations breakdown →
11.
Greenbaum, Carla J., Craig A. Beam, David Boulware, et al.. (2013). Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes Technology & Therapeutics. 15. 12 indexed citations
12.
Faleo, Gaetano, Carmen Fotino, R. Damaris Molano, et al.. (2012). Prevention of Autoimmune Diabetes and Induction of β-Cell Proliferation in NOD Mice by Hyperbaric Oxygen Therapy. Diabetes. 61(7). 1769–1778. 34 indexed citations
13.
Greenbaum, Carla J., Craig A. Beam, David Boulware, et al.. (2012). Fall in C-Peptide During First 2 Years From Diagnosis. Diabetes. 61(8). 2066–2073. 235 indexed citations
14.
Ferrannini, Ele, et al.. (2009). Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset. Diabetes. 59(3). 679–685. 110 indexed citations
15.
Skyler, Jay S., Richard M. Bergenstal, Robert O. Bonow, et al.. (2008). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Diabetes Care. 32(1). 187–192. 637 indexed citations breakdown →
16.
Sosenko, Jay M., Jerry P. Palmer, Lisa Rafkin‐Mervis, et al.. (2008). Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1. Diabetes Care. 31(11). 2188–2192. 62 indexed citations
17.
Skyler, Jay S.. (2005). Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes. Diabetes Care. 28(5). 1068–1076. 478 indexed citations
18.
Cockram, Clive S., Norio Hotta, S. M. Marshall, et al.. (2002). Instructions to authors. Diabetes Research and Clinical Practice. 57(1). 73–74.
19.
Donahue, Richard P., Richard P. Donahue, Paul Zimmet, et al.. (1999). Cigarette Smoking, Alcohol Use, and Physical Activity in Relation to Serum Leptin Levels in a Multiethnic Population. Annals of Epidemiology. 9(2). 108–113. 76 indexed citations
20.
Ryan, Edmond A., J. Miller, & Jay S. Skyler. (1983). Finger sepsis: possible complication of self monitoring of blood glucose concentrations.. BMJ. 286(6378). 1614.2–1615. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo Pozzilli Breakdown of academic impact, for papers by Marian Rewers Breakdown of academic impact, for papers by Desmond Schatz Breakdown of academic impact, for papers by David M. Maahs Breakdown of academic impact, for papers by David M. Nathan Breakdown of academic impact, for papers by James H. Warram Breakdown of academic impact, for papers by H. Peter Chase Breakdown of academic impact, for papers by Santica M. Marcovina Breakdown of academic impact, for papers by Abbas E. Kitabchi Breakdown of academic impact, for papers by Zhiguang Zhou
Rankless by CCL
2026